"Dengue Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
| Descriptor ID |
D053059
|
| MeSH Number(s) |
D20.215.894.899.162
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dengue Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Dengue Vaccines".
This graph shows the total number of publications written about "Dengue Vaccines" by people in this website by year, and whether "Dengue Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dengue Vaccines" by people in Profiles.
-
Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. Hum Vaccin Immunother. 2019; 15(9):2090-2105.
-
Next generation designer virus-like particle vaccines for dengue. Expert Rev Vaccines. 2019 02; 18(2):105-117.
-
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. Am J Trop Med Hyg. 2017 Jan 11; 96(1):126-134.
-
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies. BMC Biotechnol. 2016 06 14; 16(1):50.
-
Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children. Am J Trop Med Hyg. 2016 06 01; 94(6):1348-1358.
-
Dengue viruses cluster antigenically but not as discrete serotypes. Science. 2015 Sep 18; 349(6254):1338-43.
-
Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014 Jul; 91(1):119-28.
-
Dengue virus and Japanese encephalitis virus epidemiological shifts in Nepal: a case of opposing trends. Am J Trop Med Hyg. 2013 Apr; 88(4):677-80.
-
Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis. 2011 Aug 01; 204(3):442-50.
-
Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus. Virus Genes. 2011 Aug; 43(1):18-26.